Clinical trial
Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination…
NCT00481455 · CASI Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00481455 |
|---|---|
| Title | Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM) |
| Official title | A Single-Center, Open-Label, Phase II, Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Combination With Protracted Oral Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme |
| Lead sponsor | CASI Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Glioblastoma Multiforme |
| Intervention type | Drug |
| Interventions | Panzem NCD, Temozolomide |
| Enrollment | 15 |
| Start date | Apr 1, 2007 |
| Primary completion | Sep 1, 2007 |
| Completion | Oct 1, 2008 |
| First posted | Jun 1, 2007 |
| Last update posted | Nov 25, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: